Financial

Johnson & Johnson to break ground on new state-of-the-art biologics facility in North Carolina to deliver market-leading portfolio of transformational therapies

•New facility will support plans to advance J&J's portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases

•Delivering on Company's plans for increased U.S. investment, $2 billion+ advanced biologics facility will add more than 5,000 high-wage manufacturing and construction jobs in North Carolina.

•Investment will create an estimated economic impact of $3 billion statewide during first 10 years of site operation

March 21, 2025

Share

Listen to this article now

1.0x

00:00

07:58

New Brunswick, N.J., MARCH 21, 2025 – Johnson & Johnson (NYSE: JNJ) (the "Company") today will break ground on its new, 500,000 square foot, state-of-the-art biologics manufacturing facility in Wilson, North Carolina, which will

Janssen Biotech, Inc.
Exhibit 2012
Accord v. Janssen
IPR2026-00256, -00257, -00258, -00259
Ex. 2012-001

"Company") today will break ground on its new, 500,000 square foot, state-of-the-art biologics manufacturing facility in Wilson, North Carolina, which will expand its capacity to deliver transformational medicines for people living with cancer, immune-mediated and neurological diseases. The groundbreaking will be marked by an event that features perspectives from key Company leaders and national, state and local officials on the impact of this investment for patients and the community at large. This event represents a significant milestone as part of the Company's announcement that it is increasing its U.S. research and development, technology and manufacturing investments to more than $55 billion over the next four years.

"We are pleased to make this significant investment in our manufacturing network in the United States. This state-of-the-art biologics facility in North Carolina will help Johnson & Johnson to accelerate the delivery of our portfolio and pipeline of transformational medicines for patients," said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson. "This $2 billion investment will bring more than 5,000 high-wage manufacturing and construction jobs to North Carolina and the partnerships we are forging in the community will support local educational initiatives to develop the workforce of the future."

"Wilson is an important life sciences hub, and I am excited to welcome Johnson & Johnson as it expands its manufacturing footprint in our state," said Governor Josh Stein. "I look forward to seeing the impact this investment will have on medical innovation and North Carolina's workforce."

This investment builds on Johnson & Johnson's 140-year manufacturing heritage, with a significant existing footprint in the U.S. where the company already employs people in Innovative Medicine and MedTech manufacturing roles across its sites. Once fully operational, this state-of-the-art, digitally enabled facility will directly employ over 500 specialized employees and contractors, including process technicians, laboratory analysts, engineers and microbiologists.

These new jobs have the potential to create a payroll impact of approximately $45 million for the region each year. Additionally, the Company estimates it could create approximately 5,000 construction jobs during the development of the site and that the investment will create an estimated economic impact of $3 billion statewide during the first 10 years of site operation.

"This announcement by J&J to invest more than $2 billion in Wilson reaffirms that North Carolina is a powerhouse for innovation and economic growth in the life sciences industry," said Senator Thom Tillis. "Our commitment to talent, cutting-edge technology, and a thriving business ecosystem makes our state the prime destination for groundbreaking investments like J&J's new biologics facility, which

edge technology, and a thriving business ecosystem makes our state the prime destination for groundbreaking investments like J&J's new biologics facility, which will accelerate the production of transformative medicines."

In addition to creating American jobs, Johnson & Johnson is committed to supporting local education in the Wilson community and investing to grow the workforce of the future. The Company will build on its long-standing collaboration with the Smithsonian Science Education Center, in partnership with Wilson County Schools, to bring additional STEM programming to local schools. Johnson & Johnson will also support the implementation of the BioWork certificate program in all Wilson County high schools, in collaboration with the North Carolina Biotechnology Center and Wilson Community College. Through the BioWork program, students in Wilson will have an accelerated pathway to gain skills necessary to begin a career at Johnson & Johnson and other life sciences manufacturers across the state.

"Johnson & Johnson is a recognized industry leader in pharmaceutical research, development and manufacturing, and we are proud to be part of the Wilson community," said Dapo Ajayi, Vice President, Innovative Medicine Supply Chain, Johnson & Johnson. "This is a major investment and an exciting time as we start construction on this advanced manufacturing facility, using the latest technology and building a highly skilled workforce to deliver on our promise to patients."

ABOUT JOHNSON & JOHNSON

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

Learn more at https://www.jnj.com/ or at https://innovativemedicine.jnj.com/

Follow us at @JNJInnovMed.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent

materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory actions; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

This press release was updated with U.S. Senator Thom Tillis' quote on March 25, 2025.

Media contact:
Michael Amos
MAmos@ITS.JNJ.com
+41 76 560 8145

Investor contact:
Lauren Johnson
investor-relations@its.jnj.com

Document title: Johnson & Johnson to break ground on new state-of-the-art biologics facility in North Carolina to deliver market-leading portfolio of transformational…
Capture URL: https://www.jnj.com/media-center/press-releases/johnson-johnson-to-break-ground-on-new-state-of-the-art-biologics-facility-in-north-carolina-to-deliver-…
Capture timestamp (UTC): Fri, 08 May 2026 05:36:28 GMT

Media contact:
Michael Amos
MAmos@ITS.JNJ.com
+41 76 560 8145

Investor contact:
Lauren Johnson
investor-relations@its.jnj.com

This website is intended for U.S. audiences only.
Do not sell or share my personal information
Limit the use of my sensitive personal information

© Johnson & Johnson and its affiliates 2026

PageVault

Document title:	Johnson & Johnson to break ground on new state-of-the-art biologics facility in North Carolina to deliver market-leading portfolio of transformational therapies
Capture URL:	https://www.jnj.com/media-center/press-releases/johnson-johnson-to-break-ground-on-new-state-of-the-art-biologics-facility-in-north-carolina-to-deliver-market-leading-portfolio-of-transformational-therapies
Page loaded at (UTC):	Fri, 08 May 2026 05:36:07 GMT
Capture timestamp (UTC):	Fri, 08 May 2026 05:36:28 GMT
Capture tool:	10.80.0
Collection server IP:	54.145.42.72
Browser engine:	Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) @page-vault/browser/10.80.0 Chrome/144.0.7559.236 Safari/537.36
Operating system:	Linux (Node 24.14.0)
PDF length:	6
Capture ID:	3eo5AVn3QgEptGvc24mqog
Display Name:	Alan.Man

PDF REFERENCE #: ajyM6TWyxLy36TMPmvn18T